Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019

Metabolism, Год журнала: 2024, Номер 158, С. 155958 - 155958

Опубликована: Июнь 26, 2024

Язык: Английский

---

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Clinical and Molecular Hepatology, Год журнала: 2024, Номер 30(3), С. 577 - 579

Опубликована: Март 6, 2024

Язык: Английский

---

Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication

Hepatology Research, Год журнала: 2024, Номер 54(8), С. 729 - 735

Опубликована: Июнь 17, 2024

Extrahepatic malignancies are the leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD). Of these cancers, pancreatic cancer is one most lethal; however, link between NAFLD and remains unclear. Recently, various research results have been reported on association cancer, compiling this information revealed following. First, prevalence at 0.26%. Second, currently evident pathogenesis includes intrapancreatic risk factors, such as: (1) non-alcoholic pancreas disease, (2) intraductal papillary mucinous neoplasm; extrapancreatic insulin resistance adipocytokines, proinflammatory cytokines, (3) dysbiosis. Finally, metformin sodium-glucose cotransporter 2 inhibitors may reduce diabetes NAFLD. In review, we summarize recent evidence epidemiology mechanisms for NAFLD-related cancer. We further discuss impact anti-diabetic medication

Язык: Английский

---

Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease

JGH Open, Год журнала: 2024, Номер 8(6)

Опубликована: Июнь 1, 2024

The application of indices in the context metabolic dysfunction-associated steatotic liver disease (MASLD) remains unexplored. We aimed to validate ability alanine aminotransferase (ALT), fatty index (FLI), and hepatic steatosis (HSI) identify MASLD during health checkups.

Язык: Английский

---

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Clinical and Molecular Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Июнь 27, 2024

In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring progression, predicting development liver-related complications, and treatment response are crucial.The advantage simple fibrosis scores lies in their widespread accessibility through routinely performed blood tests extensive validation different clinical settings.They have shown reasonable accuracy diagnosing advanced good performance excluding majority patients with a low risk complications.Among elevated serum scores, more specific imaging biomarker has proved useful to accurately identify at biomarkers, enhanced is most widely utilized been approved United States as prognostic biomarker.For availability vibration-controlled transient elastography largely improved past years, enabling use stiffness measurement (LSM) accurate assessment significant fibrosis, cirrhosis.Combining LSM other available enhances ability diagnose at-risk steatohepatitis; predict some reaching an comparable that biopsy.Magnetic resonance imaging-based modalities provide quantification though current utilization limited research settings.Expanding future practice depends on factors such cost facility availability.

Язык: Английский

---

Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma

Cells, Год журнала: 2025, Номер 14(6), С. 428 - 428

Опубликована: Март 13, 2025

Hepatocellular carcinoma (HCC) is the sixth most common cancer and third leading cause of deaths worldwide. The etiology HCC has now dramatically changed from viral hepatitis to metabolic dysfunction-associated steatotic liver disease (MASLD). main pathogenesis MASLD-related hepatic lipid accumulation hepatocytes, which causes chronic inflammation subsequent progression fibrosis. Chronic generates oxidative stress DNA damage in contribute genomic instability, resulting development HCC. Several molecular pathways are also linked MASLD. In particular, MAPK PI3K-Akt-mTOR upregulated MASLD, promoting survival proliferation cells. addition, MASLD been reported enhance patients with infection. Although there no approved medication for besides resmetirom USA, some preventive strategies onset Sodium-glucose cotransporter-2 (SGLT2) inhibitor, a class medications, exert anti-tumor effects on by regulating reprogramming. Moreover, CD34-positive cell transplantation improves fibrosis intrahepatic angiogenesis supplying various growth factors. Furthermore, exercise through an increase energy consumption as well changes chemokines myokines. this review, we summarize recent progress made pathogenic mechanisms MASLD-associated introduced new therapeutic preventing based

Язык: Английский

---

Efficacy of measuring natural killer-activating receptor ligands to predict the pathogenesis of metabolic dysfunction-associated steatotic liver disease

Hepatology International, Год журнала: 2025, Номер unknown

Опубликована: Март 14, 2025

Язык: Английский

---

C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1

Metabolism, Год журнала: 2025, Номер unknown, С. 156242 - 156242

Опубликована: Март 1, 2025

Язык: Английский

---

Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

Clinical and Molecular Hepatology, Год журнала: 2024, Номер 30(4), С. 962 - 964

Опубликована: Май 21, 2024

Язык: Английский

---

Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases

Annals of Hepatology, Год журнала: 2024, Номер 30(1), С. 101750 - 101750

Опубликована: Дек. 4, 2024

Recently, Delphi consensus proposed an overarching term steatotic liver disease (SLD), with various subcategories such as MASLD, MetALD and ALD. Our aim was to investigate the association between MASLD/MetALD/ALD four intrahepatic extrahepatic diseases (liver diseases, renal cardiovascular cancers) in UK Biobank cohort. By defining hepatic steatosis image-derived phenotype (IDP)-PDFF >5.21%, we used data from diagnose MASLD/ MetALD/ALD. The odd ratio (OR) hazard (HR) were calculated using logistic regression modals Cox models, respectively. Among 39,230 eligible individuals, 6,865 MASLD subjects, 2,379 subjects 884 ALD diagnosed. last follow-up time October 13, 2023. Consistent analyses, significantly associated a higher risk of (HR=3.04 [95%CI:2.60-3.56], HR = 2.69 [95% CI: 2.12-3.42] =3.99 [95%CI:2.92-5.45], respectively). Subjects also had increased (HR 1.40 [95%CI:1.20-1.64]) cancers 1.36 [95%CI:1.15-1.60]). It is first study report MetALD, common based on magnetic resonance imaging data-PDFF. We found that factors for diseases. Meanwhile, factor cancers.

Язык: Английский

---